Landscapes / Companies
InnoCare Pharma Inc. not checked
FollowEvery new trial, moved date and filing, and a Monday email
Drugs
2
in active trials · 4 in all
Trials
2 active
5 since 2021
Drugs2
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Bruton's tyrosine kinase inhibitor |
Beijing InnoCare Pharma Tech |
Approved in China | 25 Jun 2031Phase 3 trial completes | ||
| How it works | Blocks BTK | ||||
| Next date | 25 Jun 2031 · Phase 3 trial completes | ||||
| Also tested for | Mantle Cell Lymphoma | ||||
| Open drug page | |||||
Mesutoclaxnot checked |
— |
Beijing InnoCare Pharma Tech |
Phase 1 | 25 Jun 2027Phase 1 trial completes | |
| Next date | 25 Jun 2027 · Phase 1 trial completes | ||||
| Also tested for | Mature B-cell Malignancies | ||||
| Open drug page | |||||
About
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 Industry-sponsored drug trials since 2021